The Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) share price is in focus after the company upgraded its FY26 revenue guidance to approximately $2.30 billion and lifted its net profit outlook.
Image source: Getty Images
What did Fisher & Paykel Healthcare report?
- Full-year FY26 operating revenue now expected to be around $2.30 billion (previously $2.17–$2.27 billion)
- Net profit after tax (NPAT) raised to between $450 million and $470 million (previously $410 million–$460 million)
- Guidance assumes NZ:US exchange rate of 60 cents as at 31 January 2026
- Updated figures do not include any potential US tariff refunds
What else do investors need to know?
Fisher & Paykel Healthcare reported strong growth across its full range of Hospital products, contributing to the upgraded guidance. The company noted ongoing improvements in gross margin and operating margin, supported by efficiency gains and continuous improvement activities.
A major regulatory update came as the United States Supreme Court overturned tariffs imposed under the IEEPA, but Fisher & Paykel Healthcare continues to work through the refund process and potential implications. Management expects to provide a further update on any tariff impacts with the full-year results in May.
What did Fisher & Paykel Healthcare management say?
Managing Director and CEO Lewis Gradon said:
We have continued to see good growth across the full range of our Hospital products so far during our second half.
Continuous improvement activities and other efficiency gains are also contributing to improvements in our gross margin and operating margin.
What's next for Fisher & Paykel Healthcare?
Looking ahead, management will provide more detail on tariff developments and possible refunds when announcing its full-year results. The company remains confident that cost increases from tariffs will be mitigated over time by ongoing efficiency efforts.
Fisher & Paykel Healthcare continues to focus on innovation, expanding its footprint in respiratory care, and driving sustainable, profitable growth. The company maintains that the long-term strategy and direction are unchanged.
Fisher & Paykel Healthcare share price snapshot
Over the past 12 months, Fisher & Paykel shares have risen 2%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 9% over the same period.
